Last Updated : July 28, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Pemazyre | pemigatinib | Cholangiocarcinoma | Do not reimburse | Complete | ||
Perjeta | pertuzumab | Early stage breast cancer | Do not reimburse | Complete | ||
Perjeta Herceptin Combo Pack | Pertuzumab | Metastatic Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Perjeta or Perjeta-Herceptin Combo Pack | Pertuzumab | Neoadjuvant Breast Cancer | Do not reimburse | Complete | ||
Perjeta-Herceptin Combo Pack | Pertuzumab-Trastuzumab Combo Pack | Early Breast Cancer | Do not reimburse | Complete | ||
Perseris | risperidone | Schizophrenia, adults | Reimburse with clinical criteria and/or conditions | Complete | ||
Pheburane | Sodium phenylbutyrate | Urea cycle disorders | List | Complete | ||
Picato | Ingenol mebutate | Actinic keratosis | Do not list | Complete | ||
Picato | Ingenol mebutate | Actinic keratosis | N/A | Complete | ||
Pifeltro | doravirine | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete |